UPDATE: Inovio Pharma (INO) CEO Targets Zika Vaccine Testing in Humans This Year - Bloomberg

January 28, 2016 3:31 PM EST
Get Alerts INO Hot Sheet
Price: $1.73 -2.26%

Overall Analyst Rating:
    NEUTRAL (= Flat)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - January 28, 2016 3:41 PM EST)

Inovio Pharma (NASDAQ: INO) CEO J. Joseph Kim said in a phone interview with Bloomberg that it plans to start testing its DNA-based Zika vaccine in non-human primates. Currently the vaccine is being tested on lab mice, but it is able to move faster than traditional vaccine development timelines. Testing in humans is targeted for this year.

Kim has been in talks with U.S. agencies about a potential Zika vaccine, and he sees getting extensive funding from U.S. agencies and abroad.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Management Comments, Momentum Movers